Table 2.
Topics | N | O | W | OSCE | CBE | Number of respondents |
---|---|---|---|---|---|---|
Radiobiology | 5 (16,66%) | 7 (23,33%) | 14 (46,66%) | 1 (3,33%) | 3 (10%) | 30 |
Radiation physics | 5 (20,83%) | 4 (16,66%) | 11 (45,83%) | 1 (4,16%) | 3 (12,5%) | 24 |
Radiosurgery | 5 (20%) | 8 (32%) | 9 (36%) | 0 (0%) | 3 (12%) | 25 |
Brachytherapy | 3 (11,53%) | 10 (38,46%) | 10 (38,46%) | 0 (0%) | 3 (11,5″%) | 26 |
Palliative RT | 2 (7,4%) | 10 (37,03%) | 11 (40,74%) | 2 (7,40%) | 2 (7,40%) | 27 |
Breast RT | 3 (10%) | 10 (33,33%) | 12 (40%) | 2 (6,66%) | 3 (10%) | 30 |
CNS RT | 2 (7,69%) | 8 (30,76%) | 11 (42,30%) | 2 (7,69%) | 3 (11,53%) | 26 |
Head and neck RT | 3 (10,71%) | 9 (32,14%) | 11 (39,28%) | 2 (7,14%) | 3 (10,71%) | 28 |
Lung RT | 2 (6,89%) | 9 (31,03%) | 13 (44,82%) | 2 (6,89%) | 3 (10,34%) | 29 |
Gastro-intestinal RT | 2 (7,4%) | 9 (33,33%) | 11 (40,74%) | 2 (7,'%) | 3 (11,11%) | 27 |
Genito-urinary RT | 2 (7,14%) | 9 (32,14%) | 12 (42,85%) | 2 (7,14%) | 3 (10,71%) | 28 |
Gynaecologic RT | 3 (10,34%) | 10 (34,48%) | 11 (37,93%) | 2 (6,89%) | 3 (10,34%) | 29 |
Skin RT | 6 (28,57%) | 5 (23,80%) | 8 (38,09%) | 1 (4,76%) | 1 (4,76%) | 21 |
Bone and soft tissue RT | 5 (26,31%) | 7 (36,84%) | 6 (31,57%) | 0 (0%) | 1 (5,26%) | 19 |
Benign conditions RT | 7 (53,84%) | 2 (15,38%) | 3 (23,07%) | 0 (0%) | 1 (7,69%) | 13 |
Pediatric RT | 8 (50%) | 1 (6,25%) | 5 (31,25%) | 0 (0%) | 2 (12,5%) | 16 |
Toxicities of RT | 4 (15,38%) | 7 (26,92%) | 11 (42,30%) | 2 (7,69%) | 2 (7,69%) | 26 |
Toxicities management | 5 (25%) | 6 (30%) | 6 (30%) | 1 (5%) | 2 (10%) | 20 |
RT for Hematologic malignancies | 7 (36,84%) | 4 (21,05%) | 4 (21,05%) | 1 (5,26%) | 3 (15,78%) | 19 |
Economic aspects of RT | 8 (72,72%) | 1 (9,09%) | 1 (9,09%) | 0 (0%) | 1 (9,09%) | 11 |
Radiation protection | 5 (31,25%) | 4 (25%) | 5 (31,25%) | 0 (0%) | 2 (12,5%) | 16 |